DaCure Therapeutics

DaCure Therapeutics is a private Shanghai-based biotechnology company founded in 2024 that is developing degrader-antibody conjugates (DACs), a modality that combines targeted antibody delivery with targeted protein degradation. The company appears focused on oncology and potentially autoimmune disease, with a preclinical pipeline centered on antibody-guided delivery of degrader payloads to tumor-associated targets. Its disclosed lead program, DAC-1522, targets Trop-2-expressing cancers including pancreatic cancer, and conference disclosures also indicate a KRAS-directed molecular glue-antibody conjugate program, MAC-8001. DaCure has been described as operating a DAC platform and raised venture funding in early 2026 from Fuho Capital. The company also appears to have scientific links to the Shanghai Institute of Materia Medica, Chinese Academy of Sciences.